Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus

Chun-Ping Chang, Teng-Kuang Yeh, Chiung-Tong Chen, Wan-Ping Wang, Yen-Ting Chen, Chia-Hua Tsai, Yan-Fu Chen, Yi-Yu Ke, Jing-Ya Wang, Ching-Ping Chen, Tsung-Chih Hsieh, Mine-Hsine Wu, Chen-Lung Huang, Ya-Ping Chen, Hong Zhuang, Ya-Hui Chi

Mol Cancer Ther (2024) 23 (6): 766–779.

https://doi.org/10.1158/1535-7163.MCT-23-0602

Published: 04 June 2024

View article titled, Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus

Includes: Supplementary data

Journal Articles

Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody–Drug Conjugates

Brandon M. Bordeau, Toan Duc Nguyen, Joseph Ryan Polli, Ping Chen, Joseph P. Balthasar

Mol Cancer Ther (2023) 22 (4): 459–470.

https://doi.org/10.1158/1535-7163.MCT-22-0440

Published: 03 April 2023

View article titled, Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody–Drug Conjugates

Includes: Supplementary data

Journal Articles

Transient Inhibition of Trastuzumab–Tumor Binding to Overcome the “Binding-Site Barrier” and Improve the Efficacy of a Trastuzumab–Gelonin Immunotoxin

Ping Chen, Brandon M. Bordeau, Yu Zhang, Joseph P. Balthasar

Mol Cancer Ther (2022) 21 (10): 1573–1582.

https://doi.org/10.1158/1535-7163.MCT-22-0192

Published: 07 October 2022

View article titled, Transient Inhibition of Trastuzumab–Tumor Binding to Overcome the “Binding-Site Barrier” and Improve the Efficacy of a Trastuzumab–Gelonin Immunotoxin

Includes: Supplementary data

Journal Articles

An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells

Ruochen Dong, Ping Chen, Kishore Polireddy, Xiaoqing Wu, Tao Wang, Remya Ramesh, Dan A. Dixon, Liang Xu, Jeffrey Aubé, Qi Chen

Mol Cancer Ther (2020) 19 (11): 2267–2277.

https://doi.org/10.1158/1535-7163.MCT-19-0822

Published: 03 November 2020

View article titled, An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells

Includes: Supplementary data

Journal Articles

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

Ping Chen, Nathan V. Lee, Wenyue Hu, Meirong Xu, Rose Ann Ferre, Hieu Lam, Simon Bergqvist, James Solowiej, Wade Diehl, You-Ai He, Xiu Yu, Asako Nagata, Todd VanArsdale, Brion W. Murray

Mol Cancer Ther (2016) 15 (10): 2273–2281.

https://doi.org/10.1158/1535-7163.MCT-16-0300

Published: 02 October 2016

View article titled, Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

Includes: Supplementary data

Journal Articles

Abstract C13: Ascorbate induces cytotoxicity in prostate cancer cells through an autophagy pathway

Ping Chen, Brian Chalmers, Jun Yang, Benyi Li, Jeanne A. Drisko, Qi Chen

Mol Cancer Ther (2009) 8 (12_Supplement): C13.

https://doi.org/10.1158/1535-7163.TARG-09-C13

Published: 10 December 2009

View article titled, Abstract C13: Ascorbate induces cytotoxicity in prostate cancer cells through an autophagy pathway

Journal Articles

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

Alessandra Blasina, Jill Hallin, Enhong Chen, Maria Elena Arango, Eugenia Kraynov, James Register, Stephan Grant, Sacha Ninkovic, Ping Chen, Tim Nichols, Patrick O'Connor, Kenna Anderes

Mol Cancer Ther (2008) 7 (8): 2394–2404.

https://doi.org/10.1158/1535-7163.MCT-07-2391

Published: 21 August 2008

View article titled, Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

Includes: Supplementary data

NARROW

Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus

Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody–Drug Conjugates

Transient Inhibition of Trastuzumab–Tumor Binding to Overcome the “Binding-Site Barrier” and Improve the Efficacy of a Trastuzumab–Gelonin Immunotoxin

An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

Abstract C13: Ascorbate induces cytotoxicity in prostate cancer cells through an autophagy pathway

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

Email alerts

AACR Journals

Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus

Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody–Drug Conjugates

Transient Inhibition of Trastuzumab–Tumor Binding to Overcome the “Binding-Site Barrier” and Improve the Efficacy of a Trastuzumab–Gelonin Immunotoxin

An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

Abstract C13: Ascorbate induces cytotoxicity in prostate cancer cells through an autophagy pathway

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only